T cell therapy shows persistent benefits in young leukemia patients

(Children's Hospital of Philadelphia) Updated results from a global clinical trial of the CAR T-cell therapy, tisagenlecleucel, a landmark personalized treatment for a high-risk form of acute lymphoblastic leukemia (ALL), reveal that children and young adults continued to show high rates of durable, complete remission of their disease. Most side effects were short-lived and reversible.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news